II. Indications

  1. See Menactra (MCV4) which is preferred due to higher immunogenicity

III. Mechanism

  1. Quadrivalent Meningococcal Polysaccharide Vaccine
  2. Covers strains A, C, W-135, and Y (does not contain B serotype)
    1. Covers same strains as Menactra
    2. See Menactra for further explanation
  3. Cost: $100 (similar to Menactra)
  4. Storage: 35 to 46 F (2 to 8 C), Same as Menactra

IV. Dose: Menomune

  1. Adult: 0.5 ml SC every 3 years
  2. Intramuscular may be preferred over subcutaneous route
    1. Intramuscular Injection reduces adverse effects
      1. Local erythema (11% for IM, 32% for SC)
      2. Headache (3% for IM and 12% for SC)
    2. Intramuscular has same efficacy as subcutaneous route

V. Efficacy

  1. Like Menactra, Menomune has a high seroconversion rate (98%-100%)
  2. However Menomune duration is much shorter
    1. Menomune duration lasts 3 years in school age children and less in infants

VI. Precautions: Safety

  1. No longer contains Thimerosal
  2. Approved for all ages
  3. Safe in Human Immunodeficiency Virus (HIV)
    1. See Immunization in HIV

VII. Adverse effects

  1. Serious adverse events are uncommon (<1.3%)
  2. Headache
  3. Fever (in up to 3% of children)
  4. Local reactions (more common with Menactra)

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Ontology: Menomune (C0244512)

Concepts Pharmacologic Substance (T121) , Immunologic Factor (T129)
MSH D022401
French Menomune
English menomune, Sanofi Pasteur Brand of Meningococcal Polysaccharide Vaccine, Menomune